Long-term study with the staphylococcus vaccine Staphypan in treatment of patients with fibromyalgia and chronic fatigue syndrome

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001281-40-SE

Enrollment

135

Registered

2004-06-29

Start date

2004-09-23

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia M79.0 + Chronic fatigue syndrome F48.0

Interventions

Trade Name: Staphypan Product Name: Staphypan Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who fulfil the criteria of fibromyalgia and chronic fatigue syndrome and who have responded to treatment with the staphylococcus vaccine Staphypan. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: Clinical effect of long-term treatment and adverse effects;Secondary Objective: ;Primary end point(s): Ratings on the FibroFatigue scale at end of 2005.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026